Kevin Pojasek, Enara CEO

Boehringer In­gel­heim en­lists a UK start­up in a mile­stone-heavy quest for 'dark anti­gen­s'

A year af­ter rais­ing $17.5 mil­lion for a plat­form to search for so-called “dark anti­gens” lurk­ing in tu­mors, Enara Bio has nabbed a buy­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.